<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26714">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01874015</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-GI-003</org_study_id>
    <nct_id>NCT01874015</nct_id>
  </id_info>
  <brief_title>Transplantation of Bone Marrow Mesenchymal Stem Cell in Crohn's Disease</brief_title>
  <official_title>Transplantation of Bone Marrow Mesenchymal Stem Cell in Moderate to Severe Fistulizing Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, parallel, phase 1 trial to assess the safety and
      feasibility of the transplantation of bone marrow derived mesenchymal stem cells (MSCs) in
      fistulizing Crohn's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study all eligible patients were randomly allocated into two study groups by a
      permuted block randomization method: group A receives only autologous MSCs suspended in
      fibrin glue, group B receives autologous MSCs+ Fibroblasts. Both groups receive 4 injections
      inside the wall and lumen of the fistula. Injections will be repeated every month.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>fistula closure</measure>
    <time_frame>4months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation the fistula closure after mesenchymal cell transplantation in patients with crohn's disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CDAI</measure>
    <time_frame>4months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation the decrease of CDAI after mesenchymal cell transplantation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>mesenchymal cell and fibroblast transplantaion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients with crohn's disease who underwent mesenchymal cell and fibroblast  injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mesenchymal cell transplantaion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients with Crohn's disease who underwent mesenchymal cell transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal cell transplantation</intervention_name>
    <description>Mesenchymal cell transplantation in patients with Crohn's disease.</description>
    <arm_group_label>mesenchymal cell transplantaion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal cell and fibroblast injection</intervention_name>
    <description>Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.</description>
    <arm_group_label>mesenchymal cell and fibroblast transplantaion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1- Poor response to routine treatments in refractory Crohn's disease with fistula.

             2- CDAI&gt;220 3- Age 18 to 60 years 4- GFR&gt;30, Cr&lt;2 5- The presence of perinea fistula.

        Exclusion Criteria:

          -  pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Royan department of degenerative medicine,Head of Royan celltherapy center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahdi Mohammad Nejhad, MD</last_name>
    <role>Study Director</role>
    <affiliation>TUMS DDRI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <phone>+9823562000</phone>
    <phone_ext>504</phone_ext>
    <email>nasser.aghdami@royaninstitute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leila Arab, MD</last_name>
    <phone>+9823562000</phone>
    <phone_ext>414</phone_ext>
    <email>Leara91@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nasser Aghdami, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Massoud Vosough, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>vagihe azimian, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://Royaninstitute.org</url>
  </link>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>May 10, 2014</lastchanged_date>
  <firstreceived_date>June 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's disease</keyword>
  <keyword>mesenchymal stem cell</keyword>
  <keyword>fistula</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
